Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
Launched by SANTEN SAS · Apr 22, 2008
Trial Information
Current as of June 17, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • M \& F 18 years and older
- • Diagnosed with diabetes mellitus and presenting diabetic retinopathy
- Exclusion Criteria:
- • Monocular
- • History of current ocular hypertension or glaucoma in either eye defined
- • Any significant ocular disease (other than diabetic retinopathy)
About Santen Sas
Santen SAS is a leading pharmaceutical company specializing in the development and commercialization of innovative ophthalmic products. With a strong commitment to improving the quality of life for patients with eye diseases, Santen focuses on research-driven solutions in areas such as glaucoma, retinal disorders, and dry eye disease. Leveraging extensive expertise in ophthalmology, Santen SAS engages in collaborative partnerships and clinical trials to advance therapeutic options and enhance patient care. The company is dedicated to scientific excellence and aims to provide high-quality treatments that address unmet medical needs in the global eye care market.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Indianapolis, Indiana, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials